Published January 17, 2015 | Version v1
Publication Open

PARP inhibitors

  • 1. Dow University of Health Sciences

Description

Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs.

⚠️ This is an automatic machine translation with an accuracy of 90-95%

Translated Description (Arabic)

بوليميرازات بولي (ADP - ريبوز)، التي يتم اختصارها باسم PARPs، هي مجموعة من البروتينات المألوفة التي تلعب دورًا مركزيًا في إصلاح الحمض النووي باستخدام مسار إصلاح استئصال القاعدة (BER). هناك حوالي 17 بروتينًا في هذه العائلة منها PARPs النووية الأولية هي PARP -1 و PARP -2 و PARP -3 و tankyrases 1 و 2 (PARP -5a و -5b). من المعروف أن أفراد عائلة PARP يشاركون في مجموعة واسعة من الأنشطة الخلوية، على سبيل المثال، إصلاح الحمض النووي، والنسخ، والإشارات الخلوية، وتنظيم دورة الخلية والانقسام المتساوي من بين أمور أخرى. الوحدات الوظيفية الرئيسية لـ PARP -1 هي مجال ربط الحمض النووي للمحطة الأمينية (DBD)، ومجال التعديل التلقائي المركزي (AMD)، والمجال الحفاز لمحطة الكربوكسيل (CD). تخضع مثبطات PARP حاليًا لتجارب سريرية كطرق علاج مستهدفة لسرطان الثدي والرحم والقولون والمستقيم والمبيض. تلخص هذه المراجعة الرؤى الحالية حول آلية عمل مثبطات PARP، وتجاربها السريرية الأخيرة، والخطوات التالية المحتملة في تقييم هذه الفئة الواعدة من الأدوية المضادة للسرطان.

Translated Description (English)

Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There are about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis among others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs.

Translated Description (French)

Poly (ADP-ribose) polymerases, abréviation de PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs.

Translated Description (Spanish)

Poly (ADP-ribose) polymerases, abreviado como PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anticancer drugs.

Files

s13053-014-0024-8.pdf

Files (246.3 kB)

⚠️ Please wait a few minutes before your translated files are ready ⚠️ Note: Some files might be protected thus translations might not work.
Name Size Download all
md5:53cd2ee19a908b8aa73417e2a379eb5c
246.3 kB
Preview Download

Additional details

Additional titles

Translated title (Arabic)
مثبطات PARP
Translated title (English)
PARP inhibitors
Translated title (French)
PARP inhibitors
Translated title (Spanish)
Inhibidores PARP

Identifiers

Other
https://openalex.org/W3192994539
DOI
10.1186/s13053-014-0024-8

GreSIS Basics Section

Is Global South Knowledge
Yes
Country
Pakistan

References

  • https://openalex.org/W1825629489
  • https://openalex.org/W1877440701
  • https://openalex.org/W1925527451
  • https://openalex.org/W1964787941
  • https://openalex.org/W196575356
  • https://openalex.org/W1975445106
  • https://openalex.org/W1976164429
  • https://openalex.org/W1992332625
  • https://openalex.org/W1993582972
  • https://openalex.org/W2005458257
  • https://openalex.org/W2009007206
  • https://openalex.org/W2013537373
  • https://openalex.org/W2016637704
  • https://openalex.org/W2034058449
  • https://openalex.org/W2048305487
  • https://openalex.org/W2057706543
  • https://openalex.org/W2060654492
  • https://openalex.org/W2072528578
  • https://openalex.org/W2074163000
  • https://openalex.org/W2086038769
  • https://openalex.org/W2104335176
  • https://openalex.org/W2106059513
  • https://openalex.org/W2116005493
  • https://openalex.org/W2134902059
  • https://openalex.org/W2142658272
  • https://openalex.org/W2150144069
  • https://openalex.org/W2152127384
  • https://openalex.org/W2156077962
  • https://openalex.org/W2159682317
  • https://openalex.org/W2162460329
  • https://openalex.org/W2163138275
  • https://openalex.org/W2171972386
  • https://openalex.org/W2340291575
  • https://openalex.org/W2529952554
  • https://openalex.org/W4249199995